For elderly patients with ER positive tumors endocrine therapy is an acceptable alternative to chemotherapy with similar response rates and less toxicity.
Neoadjuvant endocrine therapy in postmenopausal women with ER +HER2 neg locally advanced breast cancer is equivocal to neoadjuvant chemotherapy as far locoregional and overall outcomes (wright JL).
NHT could downsize hormone receptor positive breast tumors and facilitate breast conserving with efficacy.
Trials comparing neuroendocrine therapy with neoadjuvant chemotherapy in hormone receptor positive negative HER2 negative breast cancer demonstrated similar clinical and radiological response and breast conserving surgery.